Funding
Funding not disclosed
Founders
Product
Problem
Access to clinical‑grade diagnostic, monitoring, and therapeutic tools is limited in low‑resource and remote settings due to bulky equipment, high bandwidth requirements, and the need for specialist operators. This hampers timely diagnosis, continuous patient monitoring, and the delivery of precision interventions.
Solution
Mecklin Research delivers a portfolio of AI‑enabled, clinical‑grade platforms that operate on low‑bandwidth networks and can be deployed in community settings. The Atria® Health ATM provides autonomous, unmanned kiosks that capture over 40 vital parameters and generate real‑time PDF reports linked to national health identifiers. The Atria® 21‑day ECG monitor runs on‑device deep‑learning arrhythmia classification with 16,430 model parameters, eliminating cloud dependency. Their telehealth platform offers HIPAA‑ and GDPR‑compliant video consultations with simultaneous transmission of ECG, SpO₂, respiration, NIBP, temperature, and EtCO₂, functional on 2G networks. Additional offerings include drug‑eluting and bioresorbable coronary stents, a wearable 32‑channel ambulatory EEG with automated seizure annotation, and a point‑of‑care CKD panel that delivers eGFR, uACR, and bioimpedance results in under eight minutes. Mecklin also provides model‑informed drug development services to accelerate pharmaceutical research. All solutions are built on a full stack of sensors, firmware, edge AI, and regulatory‑compliant validation, ensuring scalability and interoperability via FHIR/HL7 standards.
Target Audience
Primary customers include primary health centres, rural clinics, and pharmacies seeking autonomous diagnostics; hospitals and specialty physicians (cardiology, neurology, nephrology) requiring advanced monitoring and intervention tools; telemedicine providers needing low‑bandwidth, integrated vital‑sign transmission; and pharmaceutical companies looking for model‑informed drug development services.
Features
- Atria® Health ATM: unmanned kiosk delivering 40+ clinical‑grade vitals, ABDM‑linked, real‑time PDF reports, fully autonomous operation
- Atria® 21‑day ECG: continuous ambulatory monitoring with on‑device AI (16,430 parameters) for arrhythmia detection, BLE 6.0 connectivity, no cloud reliance
- Telehealth platform: HIPAA/GDPR‑compliant video calls with simultaneous ECG, SpO₂, respiration, NIBP, temperature, EtCO₂; works on 2G+ networks; AES‑256 end‑to‑end encryption; HL7/FHIR integration
- Coronary stent systems: drug‑eluting and bioresorbable cobalt‑chromium stents with 60–80 µm thin struts for reduced restenosis, CE/FDA/CDSCO pathways
- Ambulatory EEG: wearable 32‑channel system for up to 7‑day continuous monitoring, cloud‑based automated seizure annotation, 256 Hz sampling
- CKD monitoring panel: point‑of‑care eGFR, urinary albumin‑to‑creatinine ratio, and bioimpedance fluid assessment; results in <8 minutes; ABDM/EMR integration
- Quantitative pharmacology service: PK/PD, population PK, QSP modeling, virtual patient trials using NONMEM, Monolix, R; supports FDA/EMA/CDSCO submissions
- Full‑stack development: edge signal processing, ISO 13485‑compliant hardware, rapid 90‑day prototyping cycles, and bi‑directional EMR interoperability